Neoplasm of mature B-cells

This study tests a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in 50 adults with solid tumors. The goal is to see if the vaccine is safe and triggers an immune response against the cancer. Participants must have good organ function and …

This study tests a new treatment called AZD4045, which uses specially engineered immune cells (CAR-T cells) to target and kill multiple myeloma cells. The therapy is given alone or combined with other drugs (daratumumab and aldesleukin) in adults whose myeloma has returned or sto…

This trial is testing a new drug called DS1025a in people with advanced solid tumors that have spread, cannot be removed by surgery, or have stopped responding to other treatments. The main goals are to check the drug's safety, how the body processes it, and whether it shows any …

This phase 2 trial tests a treatment plan for people with newly diagnosed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Participants first take zanubrutinib alone for 12 cycles, then add sonrotoclax for another 12 cycles. The goal is to see if this seque…

This trial provides continued access to three experimental Bicycle therapies—zelenectide pevedotin, nuzefatide pevedotin, and BT7480—for people with advanced solid tumors who are already benefiting from them in another study. Participants continue their same treatment while resea…

This early-stage trial is testing a new drug called BP2202 in 24 people with multiple myeloma that has come back or no longer responds to standard treatments. The main goal is to see if BP2202 is safe and to find the best dose. Researchers will also watch for any signs that the d…

This phase 2 trial tests whether adding the targeted drug orelabrutinib to standard chemotherapy improves outcomes for people with a specific genetic subtype of diffuse large B-cell lymphoma (MCD subtype). Participants receive the drug combination during initial treatment, follow…

This 12-week study tests whether a weekly injection of tirzepatide, a drug used for diabetes, combined with motivational therapy can help adults with moderate to severe cannabis use disorder. Fifteen participants will receive escalating doses of tirzepatide along with counseling.…

This early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…

This phase 2 trial tests the drug mosunetuzumab in 30 people with chronic lymphocytic leukemia (CLL) who still have detectable cancer cells after at least six months of standard therapy. The goal is to see if the drug can clear those remaining cells and improve outcomes. Particip…

This phase 1 trial is testing a new kind of CAR-T cell therapy, called LMY-922, for people with certain blood cancers that have not responded to standard treatments. The therapy uses donor immune cells engineered to target a protein called BAFF on cancer cells. The study aims to …

This study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…

This phase 2 trial tests two oral drugs, nemtabrutinib and venetoclax, as a first treatment for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if the combination can make cancer cells undetectable in the blood. About 25 adul…

This trial tests whether adding low-dose total body irradiation (TBI) to standard chemotherapy before CAR T-cell therapy (tisagenlecleucel) is safe and effective for adults with large B-cell lymphoma that has returned or not responded to prior treatments. The study involves 18 pa…

This early-stage trial tests a new drug called SHR-4685 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 170 adults aged 18 to 75 with meas…

This phase 1 trial tests a new cell therapy called KITE-753 for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. KITE-753 is made from a patient's own immune cells, which are modified to recognize and attack leuke…

This phase 2 trial is testing whether a combination of three drugs—zanubrutinib, sonrotoclax, and obinutuzumab—can safely control chronic lymphocytic leukemia (CLL) in people who have not yet received treatment. About 40 participants will receive all three drugs orally. The main …

This study tests a self-management program called Take5Care+ for adults recently diagnosed with slow-growing blood cancers. Participants choose a healthy habit—like better nutrition or more physical activity—and commit to it for 30 days. The goal is to see if this simple approach…

This study compares a new combination of teclistamab and pomalidomide against the standard treatment (carfilzomib, pomalidomide, and dexamethasone) for multiple myeloma that has come back after improvement. About 162 adults with relapsed or refractory myeloma will take part. The …

This trial tests whether giving patients a special type of donor immune cell, called CD45RA-depleted DLI, can prevent serious viral infections after a stem cell transplant. The study includes 30 high-risk patients who have received a transplant for blood cancer. Researchers will …

This early-phase trial tests a new type of immune cell therapy called GoFast CD19 CAR T-cells in 9 adults with relapsed or refractory large B-cell lymphoma. Participants receive chemotherapy followed by an infusion of their own modified immune cells. The study aims to see if the …

This Phase 3 trial tests whether adding the drug Teclistamab to a standard treatment regimen (Daratumumab, Lenalidomide, Bortezomib, Dexamethasone) improves outcomes for newly diagnosed multiple myeloma patients eligible for stem cell transplant. About 399 adults aged 18-70 will …

This study tests a new biologic drug called XYA02 in 190 adults with advanced solid tumors (including lung, ovarian, and pancreatic cancers) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumo…

This phase 2 trial compares two drug combinations for people newly diagnosed with multiple myeloma who are not eligible for or have deferred a stem cell transplant. One group gets the experimental drug elranatamab plus standard medications (lenalidomide, bortezomib, dexamethasone…

This phase 3 trial will compare a new treatment, ramantamig plus daratumumab, against two standard drug combinations for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The study aims to see if the new combo can keep the cancer from p…

This study tests whether offering buprenorphine treatment directly at syringe service programs (SSPs) helps more people start and stay on medication for opioid use disorder compared to referring them elsewhere. About 512 adults who use SSPs and have moderate to severe opioid use …

This study tests a combination of two drugs, glofitamab and selinexor, in 30 adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have already tried at least two other treatments. The goal is to see how many patients achieve a complete response (cancer dis…

This extension trial follows patients with advanced solid tumors who are already receiving or have received gotistobart in earlier studies. The goal is to assess long-term safety and overall survival over an extended period. Participants must be 18 or older and have been part of …

This Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…

This early-stage trial tests a new drug called LY4152199 in about 215 adults with certain types of blood cancer (like follicular lymphoma or diffuse large B-cell lymphoma) that have already been treated. The drug is designed to help the body's immune cells attack the cancer. The …

This phase 2 trial tests whether adding the drug epcoritamab to standard chemotherapy (DA-EPOCH-R) helps people with high-risk Burkitt lymphoma. About 43 adults will receive the combination. The study will check how many complete at least three cycles of treatment and track overa…

This early-stage trial is testing a new cell therapy called GK01 in 10 people with advanced solid tumors that have stopped responding to standard treatments. The therapy uses the patient's own immune cells (T cells) that are trained to attack the tumor. The main goal is to check …

This pilot study tests a new device that uses radiofrequency energy to calm overactive kidney nerves, which can drive high blood pressure. Twenty adults with untreated mild hypertension will either get the real procedure or a sham (fake) one. The main goal is to see if the real t…

This study tests a new drug called LM-168 combined with other cancer treatments (tislelizumab or docetaxel) in 108 adults with advanced solid tumors. The first part finds a safe dose; the second part checks if the combination shrinks tumors. It is not yet recruiting.

This phase 2 trial is testing whether different dosing schedules of belantamab mafodotin, when combined with bortezomib and dexamethasone, can reduce the risk of serious eye problems while still controlling multiple myeloma. About 150 adults with relapsed or refractory multiple m…

This pilot study tests whether a connected blood pressure monitor, supervised daily by a healthcare assistant, helps patients with blood cancers like CLL or lymphoma stick to home monitoring. The goal is to catch and manage high blood pressure early, a common side effect of BTK i…

This study tests whether adjusting common over-the-counter medications can make immune checkpoint inhibitors work better for people with solid tumors. Participants are asked to avoid acetaminophen and cannabis/THC/CBD, while taking aspirin and loratadine (or similar antihistamine…

This early-stage trial tests LNF2105, a drug designed to target and deliver a toxin to cancer cells that have a protein called Nectin-4 on their surface. It will enroll about 294 adults with advanced solid tumors (such as bladder, breast, or lung cancer) who have run out of stand…

This early-stage trial tests a new approach to CAR-T therapy where a virus is injected directly into the bloodstream to reprogram a patient's own immune cells to attack cancer. It involves 91 adults with advanced solid tumors who have run out of standard options. The main goal is…

This phase 2 trial tests a new drug combination for adults newly diagnosed with primary plasma cell leukemia, a rare and aggressive blood cancer. The treatment includes CM336 (a bispecific antibody) plus three other drugs. The study aims to see how many patients achieve deep remi…

This phase 2 trial tests whether infliximab, a drug that blocks inflammation, can prevent cytokine release syndrome (CRS) in people with relapsed or refractory multiple myeloma receiving teclistamab or talquetamab. CRS is a common and sometimes serious side effect of these treatm…

This early-phase trial is testing a new drug, SHR-5421, in about 97 people with multiple myeloma that has come back or stopped responding to treatment. The main goal is to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the bo…

This study tests two different drugs—dexrazoxane and liposomal doxorubicin—to see which is safer and more effective at preventing heart failure in people with a type of lymphoma called DLBCL. All 60 participants will receive standard chemotherapy (R-CHOP or pola-R-CHP), and the g…

This early-stage trial tests a new drug called CS5007 in people with advanced solid tumors that cannot be removed by surgery. The drug is designed to seek out and attack cancer cells while sparing healthy ones. The study will first find the safest dose and then check if the drug …

This phase 3 trial is for people newly diagnosed with multiple myeloma who are not healthy enough for a stem cell transplant. After six months of standard treatment with daratumumab, lenalidomide, and dexamethasone, participants are assigned to different immunotherapy combination…

This study tests whether the drug elranatamab can help keep plasmablastic lymphoma, a rare and aggressive blood cancer, from returning after initial chemotherapy. About 17 adults with or without HIV who have already responded to first treatment will receive elranatamab injections…

This study tests a drug called IgPro20 in 63 adults who have a weakened immune system after receiving CAR T-cell therapy for blood cancers like lymphoma or multiple myeloma. The goal is to see if the drug can lower the number of serious bacterial infections, such as pneumonia or …

This early-phase trial will test the safety and feasibility of adding the experimental drug glofitamab to standard chemoimmunotherapy (R-CHOP) in 15 people newly diagnosed with HIV-associated large B-cell lymphoma. Glofitamab is a bispecific antibody that helps the immune system …

This phase 2 trial is testing a new drug called CM336, given alongside standard therapy, for people with high-risk multiple myeloma. The study will include 46 adults aged 18 to 75. The main goal is to see if the combination can reduce cancer cells to very low levels (MRD negativi…

This early-stage trial is testing two experimental drugs, OVV-01 and AK112, in 30 people with advanced solid tumors that have not responded to standard treatments. OVV-01 is given both into a vein and directly into the tumor, while AK112 is given into a vein. The main goals are t…

This study tests whether a year-long lifestyle program (diet, exercise, and other healthy habits) can improve key blood markers in people with MGUS or smoldering myeloma—two early, often symptom-free conditions that can lead to multiple myeloma. About 67 adults will participate, …

This study tests whether combining two drugs, inotuzumab and blinatumomab, is safe and effective for adults newly diagnosed with B-cell acute lymphoblastic leukemia (B-ALL). The trial includes 26 people aged 18 and older who are either 55+ or cannot tolerate standard chemotherapy…

This study tests a combination of two drugs, belantamab mafodotin and mezigdomide, in 44 adults with multiple myeloma whose cancer returned after treatment with CAR-T cells or bispecific antibodies. The goal is to see if the combo can control the cancer longer. The trial starts w…

This early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safe…

This trial tests whether adding a drug called axatilimab to standard CAR-T cell therapy can improve outcomes for people with high-risk large B-cell lymphomas. Axatilimab works by conditioning macrophages, a type of immune cell, to potentially help the CAR-T cells fight cancer mor…

This study tests two experimental drugs (rocbrutinib and lacutoclax) taken together to treat several types of blood cancers, including lymphoma and leukemia. The goal is to see if the combination is safe and can shrink or control the cancer. About 92 adults who have already tried…

This phase 2 trial tests lacutoclax, a daily pill that blocks a protein helping cancer cells survive, in 75 adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. Participants take the drug until their disease worsens or side effects become…

This early-phase study tests a new type of immune cell therapy (CAR T cells) that targets two proteins on cancer cells at once. It is for adults with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after other treatments. The main goal is to find a s…

This study will follow 200 Chinese patients with relapsed or refractory B-cell acute lymphoblastic leukemia who receive a CAR-T cell therapy called puzolcabtagene autoleucel. The goal is to see how well it works in everyday medical practice, measuring response rates and how long …

This study tests whether giving a single dose of tocilizumab before the cancer drug ramantamig can prevent or reduce cytokine release syndrome (CRS), a serious flu-like reaction. About 230 adults with relapsed or refractory multiple myeloma will participate. Half will get tociliz…

This Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.

This study tests whether the drug elranatamab can be given safely in an outpatient clinic instead of the hospital for people with multiple myeloma that has come back or stopped responding to treatment. About 46 adults will receive the drug along with a single preventive dose of a…

This early-phase trial tests a new cell therapy called RN9101 in 19 adults with relapsed or refractory multiple myeloma, a blood cancer that has not responded to at least two prior treatments. RN9101 is a type of CAR-T cell therapy given as a single intravenous infusion. The main…

This study tests a new combination of drugs for adults with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to previous treatment. About 46 participants will receive an experimental drug (EZH2 inhibitor) along with two other drugs (glofitamab and chemoth…

This phase II trial tests whether a drug called mosunetuzumab works better alone or combined with either zanubrutinib or polatuzumab vedotin for people with marginal zone lymphoma that has returned or stopped responding to treatment. The study will enroll 138 participants and mea…

This study compares luspatercept to epoetin for patients with blood cancers who have poor red blood cell recovery after a stem cell transplant. About 90 adults will receive either drug every three weeks for 24 weeks. The goal is to see which treatment better reduces the need for …

This study tests whether adding a new drug called revumenib to the usual treatment (blinatumomab plus chemotherapy) can better clear leftover leukemia cells in people with a specific genetic type of B-cell acute lymphoblastic leukemia (ALL) or mixed-lineage leukemia. About 90 adu…

This early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …

This study tests a new treatment called CD70.CAR NK cells for people with diffuse large B-cell lymphoma or Hodgkin lymphoma that did not respond to or came back quickly after initial therapy. The treatment uses specially designed immune cells from a donor to find and attack cance…

This study looks at whether people with chronic lymphocytic leukemia (CLL) who have been in remission for at least two years can safely stop taking their BTK inhibitor medication. The goal is to see how long they stay cancer-free without treatment, and whether stopping improves t…

This study tests whether giving radiation therapy before the immunotherapy drugs obinutuzumab and glofitamab can improve outcomes for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). About 40 adults who have already tried at least two prior treatments wil…

This study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…

This phase 3 trial tests whether acalabrutinib (a BTK inhibitor) alone or with bortezomib can lower harmful HLA antibodies that cause platelet transfusions to fail in blood cancer patients. About 42 adults with platelet transfusion refractoriness and high antibody levels will be …

This early-phase trial tests a personalized cell therapy (rapcabtagene autoleucel) in 20 adults with large B-cell lymphoma who still have traces of cancer after initial treatment. The goal is to see if the therapy can make those traces disappear, potentially lowering the risk of …

This early-stage study tests a new treatment called LVIVO-TaVec122 in 48 adults with B-cell blood cancers that have come back or not responded to standard therapy. The main goals are to check safety, find the right dose, and measure how long the treatment lasts in the body. It is…

This study tests a drug called ifinatamab deruxtecan (I-DXd) in children with solid tumors that have returned or not responded to treatment. The drug is an antibody-drug conjugate that targets cancer cells directly. The trial aims to check safety and see if tumors shrink in about…

This early-phase trial tests a new approach for high-risk multiple myeloma: a radioactive antibody that targets cancer cells, followed by a donor stem cell transplant. The antibody delivers radiation directly to myeloma cells, while chemotherapy and low-dose radiation help prepar…

This early-stage study tests a new tablet called GW01-200 in 100 people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participan…

This study tests a new drug called FG-B901, a bispecific antibody that targets two immune proteins (PD-L1 and CD40) to activate the immune system against tumors while reducing side effects. It is given alone or with chemotherapy to 264 adults with advanced solid tumors that have …

This phase II trial tests a new drug called pirtobrutinib combined with a short course of chemotherapy in 82 fit patients with untreated CLL. The goal is to achieve deep remission with undetectable cancer cells in the blood at 24 months. The treatment lasts only 15 months, aiming…

This study tests a combination of four drugs (isatuximab, iberdomide, bortezomib, and dexamethasone) in 88 adults newly diagnosed with multiple myeloma who cannot or choose not to have a stem cell transplant. The goal is to find the safest dose and see how well the drugs control …

This early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…

This Phase 3 trial is testing a personalized approach for people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant. After initial treatment with a four-drug combination (isatuximab, iberdomide, bortezomib, and dexamethasone), the next steps—consoli…

This early-phase trial is testing DQ1001, a ready-made CAR-T cell therapy that targets two proteins (BCMA and GPRC5D) on myeloma cells. It is designed for patients whose multiple myeloma has returned or stopped responding to at least three prior treatments. The study will enroll …

This Phase 3 trial tests a new drug called IBI3003 against standard treatments for people with multiple myeloma that has returned or is not responding to therapy. About 255 participants will be randomly assigned to receive either IBI3003 or a standard treatment chosen by their do…

This study tests whether the drug pirtobrutinib can help prevent relapse in people with B-cell lymphoma who have already received CAR-T cell therapy. Twenty adults will take pirtobrutinib daily for six months after their CAR-T infusion. The main goal is to see how many achieve a …

This study tests a new drug called ICP-B208 in about 539 people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors. Participants must be 18-75, have failed pr…

This study tests a new drug (SYS6006) combined with another drug (Enlonstobart) in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and works better than Enlonstobart alone. About 264 adults will tak…

This early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…

This early-phase study tests a new treatment called CAR-DC for people with advanced solid tumors (like lung, liver, or stomach cancer) that have not responded to standard care. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells. …

This early-stage trial tests a new drug called Hemay5087 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrin…

This early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…

This early-stage study tests a new tablet, FXS0683, in 228 adults with blood cancers like lymphoma or leukemia that returned or didn't respond to standard therapy. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will be clo…

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

This Phase 2 trial tests whether adding the migraine drug rimegepant to a standard CAR-T cell therapy and another immunotherapy (glofitamab) can improve outcomes for people with high-risk relapsed or refractory large B-cell lymphoma. About 100 adults will be randomly assigned to …

This early-phase trial tests a new drug called WSK-IM02 in 9 people with advanced solid tumors that have spread to cause fluid buildup around the lungs or in the belly. The drug is given directly into the chest or abdomen to see if it is safe and can shrink tumors or reduce fluid…

This early-phase trial tests a combination of two drugs, CVL006 and 9MW2821, in 108 adults with advanced solid tumors that have not responded to standard therapy. The goal is to find a safe dose and see if the combination can shrink tumors. The study is not yet recruiting.

This early-stage trial tests a new drug called CS231295 in 42 adults with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking certain proteins that help tumors grow and form blood vessels. The main goals are to check safety, find …

This early-stage trial tests the safety of a new CAR T-cell therapy, UF-KURE-BCMA, in 12 adults with multiple myeloma that has returned or not responded to other treatments. The therapy uses specially engineered immune cells to target and attack cancer cells. The main goal is to …

This early-phase study tests a new drug, BI 1831169, combined with an existing immunotherapy (nivolumab) in Japanese adults with advanced solid tumors that have spread or not responded to prior treatments. The main goal is to find a safe, tolerable dose. Up to 46 participants wil…

This study tests whether giving tocilizumab before the first dose of linvoseltamab can lower the risk of cytokine release syndrome (CRS) in people with relapsed or refractory multiple myeloma. The 30 participants have already tried at least four prior treatments. Researchers will…

This early-phase trial tests a new oral drug called golcadomide combined with standard chemotherapy drugs (pemetrexed, rituximab, and dexamethasone) in 18 adults with large B-cell lymphoma that has spread to the brain or central nervous system and has either returned or is not re…

This Phase II trial will test a combination of pomalidomide, an anti-CD20 antibody, and prednisone as a first treatment for people with indolent (slow-growing) B-cell lymphomas. About 30 adults who have not had prior therapy will receive six cycles of the combo, followed by two y…

This study tests a new way to deliver radiation for gastric MALT lymphoma. Using AI, the treatment adapts each session to better protect nearby organs. About 25 adults with early-stage disease will take part. The goal is to see if this approach is safe and effective.

This study tests whether a new drug called teclistamab, given after standard treatment and a stem cell transplant, can help people with a rare and aggressive blood cancer called plasma cell leukemia live longer. About 74 participants will receive either standard follow-up therapy…

This early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…

This study tests an experimental drug called IDP-001 in people with advanced or metastatic solid tumors, including certain lung, head and neck, and other cancers. The trial has two phases: first to check safety and find the right dose, then to see if the drug can shrink tumors. A…

This study tests a new combination of three drugs (lisaftoclax, chidamide, and rituximab) in adults with a type of blood cancer called diffuse large B-cell lymphoma that has come back or not responded to prior treatment. The goal is to find a safe and effective dose and see if th…

This early-stage trial tests a new drug called HF50 in 45 adults with advanced solid tumors that have not responded to standard treatments. HF50 is designed to target HER2 on cancer cells and boost the immune system. The main goals are to check safety, find the right dose, and se…

This early-phase study tests a new drug called IN10028 in 75 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors when used alone or with other cancer drugs. Th…

This study tests whether adding the immunotherapy drug glofitamab to standard chemotherapy (gemcitabine and oxaliplatin) works better than usual treatments for people with large B-cell lymphoma that has returned or not responded to first therapy. About 96 adults will be randomly …

This study tests a new five-drug combination for people newly diagnosed with a high-risk form of multiple myeloma. The drugs include etentamig, isatuximab, bortezomib, lenalidomide, and dexamethasone. The trial will enroll 220 participants and first check safety, then see if the …

This early-phase study tests a new kind of CAR T-cell therapy for people with multiple myeloma that has come back or not responded to at least three prior treatments. The cells are 'armored' to resist a protein (TGF-beta) that normally blocks their attack. Up to 30 adults will re…

This trial tests whether bendamustine causes fewer severe side effects than the standard fludarabine/cyclophosphamide combination when given before CAR-T cell therapy for B-cell lymphoma. About 92 people will be randomly assigned to one of the two chemotherapy regimens. The main …

This phase 3 trial will compare two drug combinations for people newly diagnosed with multiple myeloma who are not eligible for or refuse a stem cell transplant. About 500 participants will receive either belantamab mafodotin or daratumumab, both combined with standard drugs (bor…

This early-stage trial tests a new drug (non-cationic peptide-CD47 siRNA) in about 9 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a 'don't eat me' signal on cancer cells, helping the immune system recognize and attack t…

This early-stage trial tests a new drug called JH021 in 60 people with advanced solid tumors that have stopped responding to standard treatments. JH021 is a special antibody that targets two cancer-related proteins, EGFR and cMET, to potentially slow or stop tumor growth. The mai…

This early-phase study tests the safety and tolerability of a new drug called HRS-1635 in 180 adults with B-cell blood cancers that have come back or not responded to treatment. Researchers will find the best dose and watch for side effects. The goal is to control the disease, no…

This study tests a combination of three drugs (orelabrutinib, tafasitamab, and lenalidomide) as a first treatment for people with follicular lymphoma, a slow-growing blood cancer. The goal is to see how well the drugs shrink tumors and how safe they are. About 27 newly diagnosed …

This study tests a combination of two drugs, nemtabrutinib and rituximab, in about 35 adults with marginal zone lymphoma, a slow-growing blood cancer. The goal is to see if the combo is safe and can shrink or eliminate tumors. Participants will receive the drugs by mouth and thro…

This study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…

This early-phase study tests a new drug, CS08399, in people with advanced solid tumors or lymphoma that have a specific gene deletion (MTAP). The main goal is to find a safe dose and understand how the drug works in the body. About 186 participants will take part, and researchers…

This early-phase trial tests a drug called teclistamab in 30 adults with plasmablastic lymphoma that has returned or not responded to prior treatment. Teclistamab is a bispecific antibody designed to attach to both cancer cells and immune T-cells, helping the immune system attack…

This early-phase study tests the safety of a new immunotherapy that creates cancer-fighting cells inside the body for people with relapsed or refractory plasma cell neoplasms, a type of blood cancer. The treatment targets two proteins (BCMA and GPRC5D) on cancer cells. Researcher…

This phase II trial compares a new combination of daratumumab and teclistamab against standard treatments for high-risk multiple myeloma that has relapsed or not responded to therapy. About 80 adults will be randomly assigned to either the new combo or usual care. The goal is to …

This trial looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to either stop antibiotics within 24 hours or continue standard treatment. The goal is to se…

This early-phase trial tests a new drug called SYS6051 in 114 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive the drug by IV every three weeks.

This study tests whether using a blood test (MRD) after two cycles of chemoimmunotherapy can guide the use of low-dose radiation in patients with diffuse large B-cell lymphoma. Patients with detectable cancer DNA in their blood may receive targeted radiation to remaining spots on…

This Phase 2 trial tests whether adding epcoritamab, an immune-boosting drug, to standard R-CHOP chemotherapy can safely treat newly diagnosed aggressive B-cell lymphoma. About 20 adults with certain lymphoma types will receive the combination. The main goal is to check for a sid…

This study tests a text- and web-based tool called FamilyCHESS, designed to help people with moderate to severe opioid use disorder begin and stay on medication. The tool also involves a concerned family member or friend who provides support. Researchers will compare outcomes lik…

This phase 2 trial tests a combination of three drugs—acalabrutinib, venetoclax, and tafasitamab—in 35 people with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if this mix is safe and can lead to a complete response with very…

This phase 3 trial tests whether a lower dose of the chemotherapy drug cyclophosphamide can reduce side effects after a half-matched stem cell transplant for blood cancers. The standard dose often causes complications, so researchers want to see if a lower dose works just as well…

This study tests an experimental drug called SKB565 in 180 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The trial has three stages to find the safest dose, check how the drug moves through the body, and see if it shrinks tum…

This study tests a new drug called TQB2934 in 260 people whose multiple myeloma has returned or stopped responding to treatment. Participants are randomly assigned to receive either TQB2934 or one of several standard treatments chosen by their doctor. The main goal is to see if T…

This early-stage study tests a new treatment called RN1701 for people with B-cell lymphoma that has come back or not responded to other treatments. RN1701 is a type of immune cell therapy made from donor cells, designed to target two markers on cancer cells. The study will enroll…

This early-stage trial tests a new cell therapy called B019 in 48 people with relapsed or refractory B-cell non-Hodgkin's lymphoma. The main goals are to check safety and find the right dose. Researchers will also look for early signs that the treatment shrinks tumors.

This study tests whether a new drug called SCTB35, combined with standard chemotherapy, works better than the current standard treatment (rituximab plus chemo) for people whose diffuse large B-cell lymphoma has come back or stopped responding to prior therapy. About 101 adults ag…

This early-stage trial tests a new drug called rocbrutinib combined with standard chemotherapy (R-GemOx) in 42 people with a type of lymphoma (DLBCL) that has returned or not responded to treatment. The main goals are to find a safe dose and see if the combination shrinks tumors.…

This study tests whether the drug emapalumab can prevent severe side effects (cytokine release syndrome and nerve-related toxicity) in people with lymphoma or multiple myeloma receiving bispecific antibody therapy. About 60 adults will take emapalumab before their cancer treatmen…

This Phase 3 trial tests whether a new drug called SCTB35, combined with lenalidomide, works better than the standard rituximab-plus-lenalidomide combo for people with follicular lymphoma that has returned or not responded to treatment. About 93 adults aged 18-80 will take part. …

This Phase 2 trial tests a new drug called QLS4131, given under the skin, in combination with other medications for people with malignant plasma cell neoplasms like multiple myeloma. The study will compare different drug combinations to see which works best at shrinking tumors an…

This phase 2 trial tests a drug called linvoseltamab in 34 people with multiple myeloma whose cancer returned after BCMA CAR T-cell therapy. Linvoseltamab is a bispecific antibody that helps the immune system attack myeloma cells. The main goal is to see how many patients respond…

This study looks at envafolimab, a cancer drug given as a quick shot under the skin instead of a long IV drip. It is for adults with advanced solid tumors who have not responded to standard treatments. The goal is to see how well it controls tumors and what side effects occur in …

This early-phase study tests an experimental mRNA vaccine that targets the Epstein-Barr virus (EBV) in people with HIV who have lymphoma. The vaccine aims to help the immune system fight tumors linked to EBV. The study will enroll 6 adults and primarily check for safety and signs…

This study tests a new combination of drugs (mosunetuzumab and polatuzumab vedotin) plus chemotherapy for elderly patients (70 and older) with a newly diagnosed type of lymphoma called diffuse large B-cell lymphoma. The goal is to see if this approach helps more patients achieve …

This early-phase trial tests an experimental drug called FXB0871 in about 138 adults with advanced solid tumors, including non-small cell lung cancer and liver cancer, that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and se…

This study tests whether a single injection of goserelin, given just before a stem cell transplant, can help preserve ovarian function in women with blood cancers. The trial will enroll 64 women aged 14-50 and measure menstrual recovery six months after transplant. If successful,…

This phase 2 trial tests a combination of seven drugs (CL-Pola-R-CHP) in 28 adults aged 65 and older with double or triple-hit diffuse large B-cell lymphoma who are not eligible for transplant. The goal is to see how many patients achieve complete remission after six cycles of tr…

This early-phase study tests a new type of CAR-T cell therapy that uses tiny antibodies (nanobodies) to target two markers on cancer cells (CD19 and CD20). The goal is to see if it is safe and to find the best dose for people with B-cell lymphoma that has come back or not respond…

This study tests whether a single injection of goserelin, given just before a stem cell transplant, can help preserve ovarian function in women with blood cancers. The trial will enroll 64 women aged 14 to 50 and measure if their menstrual cycles return naturally within six month…

This early-phase trial is testing an experimental therapy called WTX-212C, which uses specially engineered red blood cells to treat advanced solid tumors. The study will enroll 24 adults whose cancer has not responded to standard treatments. The main goal is to check safety and f…

This study tests a chemotherapy-free combination of three drugs (sonrotoclax, zanubrutinib, and rituximab) in 52 adults with previously untreated follicular lymphoma. The goal is to see if this approach can produce deeper and longer-lasting remissions while being easier to tolera…

This study tests whether adding thiotepa to the standard melphalan treatment before a stem cell transplant can lower the chance of multiple myeloma coming back within a year. It includes 204 adults aged 18-70 whose cancer was not fully cleared by prior therapy. Participants are r…

This early-phase study tests a new drug called KIVU-305 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goal is to find a safe dose and see if the…

This phase 2 trial tests whether adding a drug called glofitamab before and after standard CAR-T cell therapy can improve outcomes for 20 adults with high-risk, relapsed or refractory large B-cell lymphoma. Participants first receive glofitamab with chemotherapy, then CAR-T cells…

This early-phase trial is testing a new cell therapy called GT719 for several immune-mediated kidney diseases, including IgA nephropathy and membranous nephropathy. The therapy uses specially engineered immune cells to target and potentially control the disease. The study will en…

This early-phase study tests a new treatment called CY-219 CAR-T cells in 18 people whose B-cell lymphoma has come back or stopped responding to standard care. The therapy uses a patient's own immune cells, modified to better recognize and attack cancer cells. The main goals are …

This early study tests a new type of immune cell therapy called Sup19 CAR-T in 9 adults with B-cell acute lymphoblastic leukemia or lymphoma. It is for patients whose cancer stopped responding to previous CD19-targeted treatments or has low levels of CD19. The main goal is to che…

This early-phase trial tests a new gene therapy called QI-019B for people with multiple myeloma that has returned or not responded to at least two prior treatments. The therapy works by creating cancer-fighting CAR-T cells directly inside the patient's body. The study will enroll…

This early-stage trial tests a new drug called BR101 in 10 people with multiple myeloma that has returned or not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look at whether the drug helps shrink the ca…

This phase II trial tests whether adding the drug axatilimab to standard care can prevent graft-versus-host disease (GVHD) in 72 blood cancer patients receiving a stem cell transplant. GVHD occurs when donor cells attack the patient's body, causing serious symptoms. Axatilimab is…

This early-stage trial tests crotoxin, a protein from rattlesnake venom, given intravenously to 24 adults with advanced solid tumors that have not responded to standard therapy. The main goal is to see if a slow dose increase can make the drug safer and better tolerated. Research…

This early-phase trial tests a new type of CAR T-cell therapy called FT836, given together with the drug daratumumab, in 12 adults with multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goal is to see if the combination is safe…

This study tests a new drug called ALK-N001 in 190 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every 2 or 3 weeks. Researchers will check if it shrinks tumors, how safe it is, and how the body processes it. The goal is…

This early-phase study tests an experimental drug called ZE94-0605 in about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for any signs of tumor shrinkage. The study is not yet recruiting.

This study tests a vaccine called KSD-101 in 80 people with blood cancers linked to the Epstein-Barr virus (EBV). The vaccine uses a patient's own immune cells to target EBV and cancer. Researchers want to see if it can shrink tumors or keep the disease from coming back.

This study tests a new drug called NX-5948 (bexobrutideg) combined with other medicines (venetoclax, and possibly rituximab or obinutuzumab) in adults with B-cell lymphoma, chronic lymphocytic leukemia, or small lymphocytic lymphoma. The goal is to see if the combination is safe …

This study tests a drug called pirtobrutinib in 40 people with mature B-cell lymphoma whose cancer has worsened or who cannot tolerate other BTK inhibitor drugs. Participants take one pill daily. Researchers will measure how many patients respond, how long the response lasts, and…

This early-phase study tests a new cell therapy called ALA-101 for people with CD19+ non-Hodgkin lymphoma or leukemia. The therapy uses donor immune cells that are specially designed to find and attack cancer cells. The main goals are to check safety and find the best dose, with …

This study tests a new drug called KHN922 in people with advanced solid tumors that have not responded to standard treatments. KHN922 is an antibody-drug conjugate designed to target HER3 proteins on cancer cells and deliver two anti-cancer drugs directly to them. The trial will …

This study compares two drugs, NX-5948 and pirtobrutinib, in about 620 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has returned or stopped responding after prior treatment with a BTK inhibitor. The main goal is to see which drug…

This early-phase study tests a new treatment called CAR19-BCMA CAR-T for people with certain blood cancers (plasma cell neoplasms or lymphomas/leukemias) that have returned or not responded to at least three prior treatments. The therapy uses a patient's own immune cells, modifie…

This study tests whether a non-invasive brain stimulation technique called rTMS, given before cognitive-behavioral therapy, can help adults with cocaine use disorder quit. Thirty participants will receive either real or sham rTMS daily for 3 weeks, followed by 12 weeks of weekly …

This study tests whether a new drug combination (C Pola R-CHP+X) works better than the standard treatment (CR-CHOP) for people with a fast-growing type of lymphoma called double-expressor diffuse large B-cell lymphoma. About 156 adults aged 18-75 who have not been treated before …

This phase 2 trial is testing two oral drugs, BGB-16673 and sonrotoclax, in 40 people with untreated chronic lymphocytic leukemia (CLL). The goal is to see if this combination can safely control the disease for a limited time, potentially reducing the need for ongoing therapy. Pa…

This early-stage study tests a new treatment called Equecabtagene autoleucel for people with multiple myeloma that has returned or stopped responding to at least three prior therapies. The treatment uses a patient's own immune cells, modified to attack a protein called BCMA on my…

This early study is testing a new treatment called RN1701 for people with B-cell lymphoma that has come back or not responded to standard treatments. RN1701 is a type of immunotherapy made from donor cells (allogeneic CAR-T) that targets two proteins on cancer cells. The main goa…

This study tests whether adding zanubrutinib to the standard R2 regimen (rituximab and lenalidomide) improves outcomes for adults with newly diagnosed follicular lymphoma. About 100 participants will be randomly assigned to receive either the new ZR2 combo or standard R2, followe…

This trial tests a new treatment called SHB-02-CD19, which uses a patient's own immune cells engineered to attack cancer cells that have a protein called CD19. It is for children and adults with B-cell cancers (like leukemia or lymphoma) that have come back or not responded to at…

This early-phase trial is testing a new chemotherapy drug called RP-001 in 66 adults with advanced solid tumors, including colorectal and pancreatic cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. It is an open-label study, …

This phase 2 trial is testing a combination of three drugs (polatuzumab vedotin, glofitamab, and tafasitamab) as a first-line treatment for people with diffuse large B-cell lymphoma or high-grade B-cell lymphoma. The goal is to see if this chemo-free approach can shrink tumors an…

This early-stage trial is testing a new treatment called CHT101 for adults with aggressive brain tumors that have returned or worsened despite standard care. CHT101 is a type of immune cell therapy (CAR T-cells) designed to recognize and attack tumor cells carrying a protein call…

This phase 2 trial tests whether adding the anti-inflammatory drug celecoxib to standard R-CHOP chemotherapy improves outcomes for people with newly diagnosed, advanced CD5-positive diffuse large B-cell lymphoma (a fast-growing type). Sixty participants will be randomly assigned …

This study tests an experimental drug called LRK-4189, given alone or with standard chemotherapy, for adults with advanced solid tumors that have not responded to prior treatment. The main goal is to check the drug's safety and find the best dose. About 120 participants will take…

This study tests a breathing machine strategy that adjusts pressure based on lung measurements to protect the right side of the heart in 180 adults with moderate to severe lung failure from pneumonia. The goal is to see if this method reduces heart strain and complications compar…

This study tests whether adding ivermectin, a drug used for parasitic infections, can improve the immune response in people with solid tumors who are already receiving immunotherapy. About 80 adults will take either a moderate or high dose of ivermectin for four weeks alongside t…

This early-stage trial tests a new biologic drug, SIG001, in 66 people with advanced solid tumors. The main goals are to check safety, find the right dose, and see how the drug behaves in the body. Participants receive SIG001 intravenously every two weeks and are monitored for si…

This phase 2 trial tests whether giving daratumumab less often (every 8 weeks, then every 16 weeks) along with lenalidomide can work as well as the standard schedule for multiple myeloma patients after a stem cell transplant. The goal is to reduce costs and clinic visits while ma…

This study tests a new treatment called SYS6055 for people with aggressive B-cell lymphoma that has come back or not responded to standard therapy. The treatment uses specially designed cells to target and attack cancer cells. The trial will check if it is safe, what dose works b…

This early study tests a new drug called MTM-H-001 in 69 adults with B-cell blood cancers (like certain lymphomas and leukemias) that have come back or stopped responding to treatment. The main goal is to check safety and find the right dose, while also seeing if it can shrink tu…

This phase 3 trial tests two immunotherapy drugs, inotuzumab and blinatumomab, in 750 children with relapsed B-cell acute lymphoblastic leukemia. The goal is to replace toxic chemotherapy with targeted, less harmful treatments to improve survival and reduce side effects. Particip…

This real-world study looks at whether polyene phosphatidylcholine injection can prevent or treat drug-induced liver injury in adults with blood cancers like leukemia and lymphoma. Researchers will review medical records of 1,000 patients to see how well the drug works and if it …

This study looks at how well the drug glofitamab works for people with a type of blood cancer called diffuse large B-cell lymphoma that did not respond to or came back after initial treatment. About 20 adults will take part, and their doctors will decide if they get glofitamab al…

This trial is for adults with multiple myeloma or Waldenstrom macroglobulinaemia. It tests whether giving certain drugs less often can control the disease as well as the standard schedule. The goal is to find the best balance between effectiveness and quality of life. About 400 p…

This study tests an experimental oral drug, BPI-572270, in 120 adults with advanced solid tumors (lung, colorectal, or pancreatic cancer) that have specific RAS gene mutations. The trial has two phases: first to find a safe dose and check for side effects, then to see if the drug…

This Phase 2 trial tests lisaftoclax, an oral drug that blocks a protein helping cancer cells survive. It enrolls 75 adults with certain slow-growing lymphomas (CLL, WM, or MZL) who either cannot take standard BTK inhibitors due to health issues or have stopped them due to side e…

This study tests a new drug called LCB02A for people with advanced solid tumors that have a specific marker (CLDN18.2) and haven't responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The trial has two phases: first, finding the safe…

This early-phase study tests a new drug called QLS5308 in about 192 adults with advanced solid tumors that have spread and cannot be removed by surgery or radiation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants m…

This early-phase trial tests a personalized cell therapy called CART-BCMA in 3 Thai patients with multiple myeloma that has returned or stopped responding to at least three prior treatments. The therapy uses the patient's own immune cells, modified in a lab to target and kill mye…

This study tests an experimental drug called SG2918 in 40 people with relapsed or refractory multiple myeloma, a type of blood cancer that has returned or stopped responding to standard treatments. The main goal is to check the drug's safety and how well the body tolerates it, wi…

This study tests an experimental drug called QLS5132, given with other cancer treatments, for people with advanced solid tumors like stomach, lung, endometrial, and ovarian cancers. The goal is to find safe doses and see if the combination shrinks tumors. About 626 participants w…

This study tests if luspatercept can help people with blood cancers who have severe anemia after a stem cell transplant. The goal is to see if the drug reduces the need for red blood cell transfusions. About 20 adults aged 18-60 will take part. This is a phase 2 trial, meaning it…

This early-phase trial tests a new type of immunotherapy called CD70 CAR T cells in people with lymphoma, myeloma, and certain solid tumors (like kidney cancer and sarcomas) that have come back or not responded to standard treatments. The immune cells are modified in the lab to r…

This study tests whether giving focused, high-dose radiation (SBRT) to tumors outside the bone marrow before a donor stem cell transplant can improve outcomes for adults with blood cancers like leukemia or lymphoma. About 20 participants aged 18-60 will receive this combination t…

This early-stage study tests a new treatment using special immune cells (CAR-T cells) designed to reduce harmful antibodies that can prevent or damage bone marrow transplants. About 18 people with blood diseases who have these antibodies will receive the cells in increasing doses…

This early-phase trial is testing a new type of immune cell therapy called CD19X CAR-T for people with large B-cell lymphoma that has come back or not responded to other treatments. Only 3 participants will receive the therapy after a short course of chemotherapy to prepare their…

This study tests a special chemotherapy combination followed by a single umbilical cord blood transplant in 44 patients aged 60-69 with blood cancers. The goal is to see if this approach is safe and reduces the risk of cancer returning within 180 days. Participants receive severa…

This study tests a combination of two drugs, pomalidomide and obinutuzumab, in people with slow-growing lymphomas (like follicular lymphoma) that have returned or not responded to prior therapy. The first part finds the safest dose, and the second part checks how well the combina…

This phase 2 trial tests whether giving two bispecific antibodies (teclistamab and talquetamab) in sequence, along with other drugs, can improve survival in 50 people with high-risk multiple myeloma. Some participants may also receive a stem cell transplant if cancer cells remain…

This study tests a special way to process donated stem cells to make transplants safer for people with leukemia or lymphoma. The goal is to reduce serious complications like graft-versus-host disease, where donor cells attack the patient's body. About 100 participants will receiv…

This trial tests whether two approved drugs, dabrafenib and trametinib, can treat rare cancers that have a specific genetic change called BRAF V600. These drugs are already used for melanoma and lung cancer, but researchers want to see if they help people with other cancer types.…

This early-phase study tests a new treatment called CAR BCMA-CD70 CAR-T for people with high-risk plasma cell neoplasms, a type of blood cancer. The therapy uses the patient's own immune cells, modified to target two cancer markers (BCMA and CD70), to attack the disease. The main…

This early-phase trial is testing a new drug called IBI3003 in about 360 people with multiple myeloma that has returned or no longer responds to standard treatments. The study has two parts: first, finding the safest and most effective dose, and then testing how well it works. Pa…

This study tests a new drug called EMB-07, which is a bispecific antibody that helps the immune system attack cancer cells. It is for people with aggressive B-cell non-Hodgkin lymphoma, either newly diagnosed or whose cancer has come back. The trial will check safety, side effect…

This early-phase trial tests a new gene therapy called QI-019A for people with multiple myeloma that has come back or stopped responding to treatment. The therapy works by turning a patient's own immune cells into cancer-killing cells directly inside the body. The study will enro…

This early-stage study tests a new drug called T320 in 150 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive T320 every two wee…

This study tests a drug called cosibelimab in 80 people with advanced skin cancer who also have a kidney transplant or a blood cancer. The drug works by helping the immune system attack cancer cells. Researchers will check if the tumors shrink and monitor for side effects.

This early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…

This early-stage trial tests a daily pill called APG-3288 in 180 adults with blood cancers like leukemia or lymphoma that have come back or not responded to standard treatments. The main goals are to find the safest dose and check for side effects. Researchers will also look for …

This early-stage trial is testing a new treatment called SENL103 for people with multiple myeloma that has returned or not responded to standard treatments. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The study will enroll 24 parti…

This study aims to bring CAR-T cell therapy to Colombia for people with certain blood cancers that have come back or not responded to treatment. It has two parts: first, setting up the necessary partnerships and facilities to produce the therapy locally, and second, testing the s…

This phase 2 trial tests a combination of zanubrutinib (a targeted drug) plus chemotherapy for people newly diagnosed with central nervous system lymphoma. Nineteen participants will receive the treatment, with an extra drug for those with a specific gene mutation. The goal is to…

This early-phase trial tests a new type of cell therapy called CAR-Macrophages in 20 adults with advanced solid tumors. The immune cells are modified to target specific markers on cancer cells (HER2, PSMA, FAP) and are given by IV. The main goals are to check safety, find the bes…

This early-phase study tests whether giving a bispecific antibody (CM336) before CAR-T cell therapy can improve outcomes for people with relapsed or refractory multiple myeloma — a blood cancer that has stopped responding to standard treatments. Ten adults will receive the antibo…

This phase 2 trial tests a bispecific antibody called CM336 as maintenance therapy after stem cell transplant in 20 adults with newly diagnosed multiple myeloma who still have minimal residual disease. The goal is to see if it can clear remaining cancer cells and delay relapse.

This early-phase trial tests a new cell therapy called SL4903 for people with multiple myeloma that has come back or stopped responding to standard treatments. The therapy uses a patient's own immune cells, modified to better attack the cancer. The main goal is to check safety an…

This early study tests a new treatment called CAT-101, which uses a patient's own immune cells (dendritic cells) loaded with a cancer protein (mKRAS) to help the body fight tumors. It is for people with advanced pancreatic cancer or other solid tumors that have a specific KRAS mu…

This early-phase trial tests a new treatment called LVIVO-TaVec400 for people with multiple myeloma that has come back or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to better attack cancer cells. The study will enroll 38 adults…

This study tests whether adding the experimental drug lisatoclax to standard chemotherapy (R-CHOP or Pola-R-CHP) can safely improve outcomes for people with untreated diffuse large B-cell lymphoma (DLBCL). About 122 adults aged 18-70 will take part. The goal is to see if the comb…

This phase II trial will test two different drug combinations in 70 people whose diffuse large B-cell lymphoma has returned more than a year after initial treatment. One group gets a modified R-MINE regimen (rituximab, ifosfamide, mitoxantrone liposome, etoposide), the other gets…

This study tests whether the drug belantamab mafodotin, given every 6 weeks alongside a steroid, can be safely used in community clinics for patients with relapsed or refractory multiple myeloma. The drug was previously removed from the market after a confirmatory study failed, b…

This phase 2 trial tests glofitamab, an antibody that helps immune cells attack lymphoma, in 40 adults with relapsed or refractory diffuse large B-cell lymphoma who are eligible for a stem cell transplant. Glofitamab is given before transplant as a 'bridge' to shrink the cancer, …

This study tests a new treatment called BCMA-GPRC5D CAR-T for people with multiple myeloma that has come back or not responded to at least three prior treatments. The therapy uses a patient's own immune cells, modified to attack two cancer targets. The goal is to see if it is saf…

This Phase 3 trial tests whether adding the experimental drug IMM0306 to standard lenalidomide can improve outcomes for people with follicular lymphoma that has returned or stopped responding to treatment. About 198 participants will be randomly assigned to receive either IMM0306…

This early-phase trial tests a new type of immune cell therapy called GPRC5D CAR-T in 18 people with relapsed or treatment-resistant plasma cell disorders, such as multiple myeloma. The therapy involves giving patients a single infusion of their own modified immune cells designed…

This early-phase study tests a new treatment called QH103 for adults with B-cell lymphoma that has come back or not responded to standard therapy. QH103 uses specially engineered immune cells (CAR-γδT cells) from healthy donors to target and kill cancer cells. The main goals are …

This study tests whether a quick bedside ultrasound can help doctors decide if new mothers with preeclampsia need a diuretic (water pill) to lower their blood pressure. About 96 postpartum patients will be enrolled. The goal is to see if this approach speeds up blood pressure rec…

This early-phase trial tests a new mRNA-based drug called WGb-0302 in 20 adults with recurrent or treatment-resistant multiple myeloma and other blood cancers. The therapy uses lipid nanoparticles to deliver mRNA that targets BCMA, a protein on cancer cells. The main goals are to…

This early-phase study tests a new drug called QLS5316 in about 300 adults with advanced solid tumors (such as colorectal, stomach, head and neck, or lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, a…

This early-phase study tests whether a new cell therapy called B7-H3 CAR T cells is safe and can help children and young adults whose solid tumors have returned or stopped responding to standard treatments. About 40 participants will receive their own immune cells that have been …

This pilot study will test whether a 12-week Korean-style Mediterranean diet, combined with daily step tracking, is feasible for people with MGUS or smoldering myeloma. Twenty adults will receive dietary counseling and a wearable device to monitor activity. Researchers will measu…

This early-stage trial tests a procedure called microtransplantation (MST) combined with chemotherapy in 10 adults with advanced or relapsed solid tumors. The goal is to see if MST can help control the disease and improve recovery of blood cells after chemo. The study focuses on …

This study tests whether a remote temperature monitor can help detect fever early in children undergoing chemotherapy who are at risk of a serious infection called febrile neutropenia. About 30 children from families with social or emotional challenges will either use a wearable …

This early-phase trial tests an mRNA immunotherapy for people with tumors linked to the Epstein-Barr virus, such as nasopharyngeal cancer, gastric cancer, and lymphoma. The treatment aims to help the immune system recognize and attack cancer cells. Researchers will check safety a…

This early-phase trial tests a personalized treatment called IASO104 for people with relapsed or refractory multiple myeloma, a blood cancer that has not responded to standard therapies. IASO104 is made from a patient's own immune cells, which are genetically modified to recogniz…

This study tests a new treatment called TC011 for adults with follicular lymphoma that has come back or not responded to at least two prior therapies. TC011 is a type of CAR-T cell therapy that targets cancer cells. The main goal is to see how many patients' tumors shrink or disa…

This early-phase study tests whether adding the drug venetoclax to standard transplant preparation is safe for people with chronic kidney disease and a blood cancer. Only 3 adults aged 18-70 will take part. The goal is to see if the combination helps the new stem cells and kidney…

This early-stage trial tests a personalized cell therapy for adults with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a patient's own tumor, grow more of them in the lab, and then infuse them back after a short course of che…

This Phase 2 trial is testing a combination of three drugs—mezigdomide, carfilzomib, and dexamethasone—in 70 adults with relapsed or refractory multiple myeloma. The goal is to see if this combo can slow or stop the cancer from growing. Participants must have already tried lenali…

This early-phase trial tests a new therapy called TCR-T cells, which are immune cells engineered to recognize and attack cancer cells with specific KRAS mutations (G12V or G12D). The study will enroll 25 adults with advanced solid tumors (like colorectal or lung cancer) who have …

This study tests whether adjusting cancer drug doses for people with the Duffy null blood trait can reduce treatment delays and dangerous fevers. About 90 participants with multiple myeloma or triple-negative breast cancer will receive standard chemotherapy with modified dosing g…

This study tests a new treatment called AcNK-Sup003 for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has come back or not responded to other treatments. The goal is to see if it is safe and to find the best dose. About 28 adults will take part, and resear…

This early-stage trial tests a new drug called FXS887 in 14 people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein (ATR) that cancer cells need to repair their DNA. The main goals are to check safety, find the r…

This study tests whether adding inhaled nitric oxide (iNO) to standard care helps adults with moderate-to-severe acute respiratory distress syndrome (ARDS) survive longer. About 536 participants will be randomly assigned to receive iNO or a placebo through their ventilator. The m…

This study tests a new drug, HX111, in about 70 people with advanced solid tumors or lymphoma that has not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-stage trial, so the main focus is on safety and side eff…

This early-phase trial tests a new mRNA drug called WGb-0301 in 9 patients with B-cell cancers (like lymphoma or leukemia) that have come back or stopped responding to treatment. The drug uses lipid nanoparticles to deliver mRNA that targets a protein called CD19 on cancer cells.…

This study compares a four-drug regimen (isatuximab plus standard VRD) against the standard three-drug VRD in 117 newly diagnosed multiple myeloma patients who are not eligible for transplant and have high-risk features. The goal is to see if adding isatuximab leads to more patie…

This Phase 2 trial tests whether combining two platelet-boosting drugs (hetrombopag and rhTPO) works better than hetrombopag alone for cancer patients with dangerously low platelets from treatment. About 204 adults with solid tumors will be randomly assigned to one of the two gro…

This study tests whether combining two powerful treatments—glofitamab and CAR-T therapy—can help people with a high-risk, hard-to-treat type of large B-cell lymphoma that has come back or not responded to prior treatment. About 24 adults will receive the combination and be monito…

This study tests whether starting tube feeding right after a stem cell transplant can reduce severe gut graft-versus-host disease (GVHD) in people with blood cancers or disorders. About 112 participants will be randomly assigned to either standard care or early tube feeding. The …

This study tests an experimental oral drug called XNW34017 in 150 people with advanced solid tumors who have not responded to or cannot tolerate standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors. It is an…

This early-phase study tests a new treatment called RN1701 for people with B-cell lymphoma that has come back or not responded to standard therapy. RN1701 uses specially engineered immune cells from a donor to target and kill cancer cells. The main goals are to check safety and s…

This early study tests a new treatment called IASO206 for people with multiple myeloma that has come back or stopped responding to standard therapies. IASO206 is a type of CAR-T therapy that uses a patient's own immune cells to attack cancer cells. The trial will enroll 12 adults…

This study follows 159 Chinese patients with triple-class exposed relapsed/refractory multiple myeloma who are taking elranatamab in routine care. Researchers will track how well the drug controls the cancer, including response rates and survival. The goal is to see if elranatama…

This early study tests a new treatment for people with B-cell blood cancers that have come back or not responded to standard therapy. The treatment uses donor immune cells (CAR-T cells) designed to find and attack cancer cells. The main goal is to check if it's safe, with a small…

This study tests a drug called ivarmacitinib in 72 people with advanced solid tumors who had to stop their cancer immunotherapy because of severe immune-related side effects. The goal is to see if the drug can control those side effects and, if successful, allow patients to safel…

This study tests several new anti-cancer drugs and technologies in 600 people with rare solid tumors that have spread or cannot be removed. Participants will receive treatments matched to their tumor's unique genetic profile. The goal is to see if these therapies are safe and shr…

This early-phase study tests a new treatment called GC203 TIL, which uses a patient's own immune cells that are modified in a lab to better fight cancer. It is for adults with advanced solid tumors that no longer respond to standard therapies. The main goal is to check safety, an…

This study tests a new drug called TYK-01054 for people with advanced solid tumors that have not responded to standard treatments. The drug is taken as a capsule and works by blocking a protein (TEAD) involved in cancer growth. The trial will check safety, find the best dose, and…

This study tests whether the RSV vaccine Abrysvo can help blood cancer patients who have had a stem cell transplant or CAR-T therapy build immunity against RSV. Researchers will measure antibody levels before and after vaccination in 30 adults. The goal is to see if the vaccine t…

This early-stage study tests a new drug called QLS2313 in 124 adults with blood cancers (like lymphoma or leukemia) that returned or didn't respond to standard treatments. The main goal is to check safety and find the right dose, not to cure the disease. Participants receive the …

This study tests whether a personalized program of exercise, education, and support before a stem cell transplant can improve strength, reduce frailty, and enhance quality of life in adults with blood cancer. About 68 participants will be randomly assigned to either the prehabili…

This early-stage study tests a new treatment called KXV01 TCR Lentinvivo in 30 adults with advanced solid tumors that have not responded to standard therapies. The main goal is to check safety and find the right dose. The treatment uses a virus to deliver cancer-fighting genes in…

This early-phase trial tests an experimental drug called ISM5939, taken as a pill, in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study will first test the drug alone, then in combination with chemotherapy (cisplatin or doce…

This early-phase study tests a personalized CAR-T cell therapy made at the bedside for adults with B-cell acute lymphoblastic leukemia. The treatment uses the patient's own immune cells to target and kill cancer cells. The main goals are to check safety, find the best dose, and s…

This early-phase trial tests whether combining three drugs (golcadomide, poseltinib, and rituximab) can shrink or control tumors in people with relapsed or refractory large B-cell lymphoma. About 20 adults will take part. The goal is to see if the combination works better than cu…

This phase 2 trial tests a combination of PRaG-1 Cordycepin Tablets (from a fungus), radiation therapy, immune-boosting injections, and immunotherapy drugs in 65 adults with advanced solid tumors who have no standard treatment options. The goal is to see if this mix improves immu…

This early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …

This study tests a new way to do stem cell transplants for adults with high-risk blood cancers who don't have a fully matched donor. Doctors will use stem cells from a half-matched (haploidentical) donor and remove certain immune cells to try to prevent severe graft-versus-host d…

This early-stage trial is testing a new treatment for adults with B-cell acute lymphoblastic leukemia (B-ALL) using immune cells from donated umbilical cord blood that are engineered to attack cancer cells (UCAR-T). The study will enroll 50 participants to check safety, find the …

This early-stage trial tests an experimental drug called ACC-1898, taken as a daily pill, in adults with advanced solid tumors (like liver, kidney, or stomach cancer) that have not responded to standard treatments. The main goals are to find a safe dose and see how the body handl…

This early-phase trial tests a new drug called TB511 in people with advanced solid tumors (lung, prostate, colorectal, or liver cancer) that have stopped responding to standard care. The study has two parts: first, finding the safest dose of TB511 alone; second, testing TB511 com…

This study tests a new mRNA vaccine designed to help the immune system attack cancer cells. The vaccine targets a protein found only in tumors and is given together with an immunotherapy drug (anti-PD-1). About 60 adults with advanced solid tumors that cannot be removed by surger…

This Phase II trial is testing a combination of three drugs—glofitamab, polatuzumab vedotin, and zuberitamab—in 40 people newly diagnosed with diffuse large B-cell lymphoma. The goal is to see if this chemo-free approach can achieve complete remission early in treatment. Particip…

This early-stage study is testing a new treatment called CT1195E CAR-T cells in 30 adults with B-cell blood cancers that have come back or not responded to standard treatments. The therapy involves modifying a patient's own immune cells to better recognize and attack cancer cells…

This study tests special radioactive drugs that can both find and treat solid tumors that have spread to the brain. Ten adults with advanced breast cancer and active brain metastases will receive a single dose of a diagnostic agent to see if it lights up the brain tumors on a sca…

This early-phase trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has not responded to at least two prior therapies. Participants receive donor immune cells (NK cells) along with two antibody drugs (rituximab and tafasitamab) and a support drug (IL-2) …

This early-stage trial tests a new treatment for adults with solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein called GPC3. The…

This early-phase study tests a new treatment called KXV01 TCR Lentinvivo for people with advanced solid tumors that have not responded to standard therapies. The main goals are to check safety and find the right dose. About 30 adults aged 18 to 70 will take part, and researchers …

This study tests a new approach for primary central nervous system lymphoma (PCNSL), a rare brain cancer. It combines CAR-T cell therapy, a stem cell transplant, and two drugs (orelabrutinib and sintilimab) to see if the mix is safe and effective. The trial plans to enroll 30 adu…

This early-stage study tests a new drug, ATB-320, in 24 adults with solid tumors that have spread or are getting worse despite standard treatments. The main goal is to find a safe dose and check for side effects. Participants must provide tumor samples and have tumors that can be…

This early-stage trial will test a new immune cell therapy called CT1194D CAR-T in 20 adults with relapsed or refractory B-cell cancers (lymphoma or leukemia). The main goals are to check safety, find the right dose, and see how long the cells last in the body. Researchers will a…

This study tests whether adding brentuximab vedotin to standard chemotherapy (R-CHP) works better for people newly diagnosed with a rare, aggressive lymphoma linked to the Epstein-Barr virus. About 25 adults will receive the combination and be followed for 2 years to see if the c…

This study tests an experimental oral drug called GFH276 in people with advanced solid tumors that have RAS mutations, including pancreatic, lung, and colorectal cancers. The trial has two parts: Phase 1 finds the safest dose, and Phase 2 checks if the drug shrinks tumors. About …

This early-phase trial is testing an experimental drug called MS-553 in 12 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to treatment. The main goal is to check the drug's safety and find the right dose…

This study tests whether combining two drugs, loncastuximab tesirine and epcoritamab, can safely and effectively treat people with aggressive B-cell lymphoma that has come back or not responded to prior therapy. The trial will include 120 adults who have either not had CAR-T cell…

This study tests whether a minimally invasive heart valve repair procedure (TEER) plus standard medication can reduce hospital readmissions over two years in people with moderate mitral regurgitation that worsens with exertion. About 300 participants will be randomly assigned to …

This early-phase trial tests a personalized gene therapy called KXV01 TCR Lentinvivo Injection for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a virus to deliver cancer-fighting genes into the patient's own immune cells. The …

This study offers continued RVU120 treatment to up to 10 patients with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are already benefiting from the drug in an earlier trial. The main goal is to monitor safety and see how long patients c…

This phase 2 trial tests a drug called mosunetuzumab, given as a shot under the skin, for people with a slow-growing type of lymphoma that hasn't been treated yet. The drug works by helping the body's immune cells find and kill cancer cells. About 30 adults will receive up to 8 c…

This trial is testing whether adding a targeted drug called orelabrutinib to standard chemotherapy can improve outcomes for people newly diagnosed with primary central nervous system lymphoma, a rare type of brain cancer. About 215 participants will be randomly assigned to one of…

This early-phase trial tests whether giving a bispecific antibody (QLS32015) before CAR-T cell therapy can improve outcomes for 20 adults with relapsed/refractory multiple myeloma. The study measures how many patients respond and tracks side effects. It is a single-arm, open-labe…

This Phase 3 trial tests a new drug called TQB2825, a bispecific antibody that targets both CD3 and CD20 proteins, against standard immunotherapy for people with follicular lymphoma that has returned or not responded to treatment. About 228 participants will be randomly assigned …

This study tests a drug called Romiplostim N01 in 106 cancer patients whose platelets drop due to chemo, radiation, or immunotherapy. The goal is to see if it can safely raise platelet counts better than the current standard treatment. Patients will be randomly assigned to receiv…

This Phase 3 trial compares a new drug called CM336 against standard treatments for people with relapsed or refractory multiple myeloma who have already tried at least two prior therapies. About 280 participants will be randomly assigned to receive either CM336 or a standard-of-c…

This early-phase trial tests a new drug called BT02, a monoclonal antibody, in 116 adults with relapsed or refractory blood cancers like leukemia, lymphoma, or multiple myeloma. Participants receive the drug by IV every 2-3 weeks for up to two years. The main goals are to check s…

This early-phase trial will test a new type of immune cell therapy called bispecific AbTCR T-cells in 3 adults with relapsed or refractory B-cell lymphoma (including diffuse large B-cell, follicular, and Burkitt lymphoma). The cells are designed to target two proteins (CD19 and C…

This study tests a new radioactive tracer for PET/CT scans that targets a protein called GPRC5D found on multiple myeloma cells. About 50 adults with plasma cell disorders, including multiple myeloma, will receive the tracer and then undergo imaging. The goal is to see if this me…

This study tests a new radioactive tracer called 68Ga-FAPI-PSMA for PET/CT scans to see if it can find and stage solid tumors (like prostate, liver, and ovarian cancers) better than current tracers. About 20 adults with suspected or confirmed tumors will receive the tracer and ha…

This study explores whether a PET/MR scan using a radioactive tracer called 18F-Florbetaben can detect amyloid deposits—abnormal protein clumps that can damage organs—in people with certain blood disorders. Participants receive a single injection of the tracer followed by a whole…

This study tests a new radioactive tracer called 68Ga-MY for PET scans. It targets a protein (5T4) found on many cancer cells but rarely on healthy cells. About 20 people with lung or breast cancer will get both a standard FDG scan and a 68Ga-MY scan. Researchers will compare the…

This study aims to see if a new blood test (mNGS) can accurately diagnose invasive fungal lung infections in 1,000 people with blood disorders. Participants will provide a blood sample and undergo standard tests, then be followed for 42 days. The goal is to find a faster, more re…

This study tests a new PET imaging agent, 68Ga-cPP-BCH, to detect PD-L1 protein levels in tumors of people with lung cancer, melanoma, or other solid tumors. The goal is to see if this scan can identify who might benefit from anti-PD-1/PD-L1 immunotherapy without needing a tissue…

This pilot study will test whether an iPad app called DCog Short can spot early signs of brain-related side effects (neurotoxicity) in 40 adults receiving CAR-T cell therapy for blood cancers. Participants will use the app to self-report symptoms, and researchers will compare the…

This study tests a new type of PET/CT scan that uses a special tracer (68Ga-BCMA nanobody) to find multiple myeloma lesions in the body. Researchers will compare it to the standard FDG-PET/CT scan in 30 patients with newly diagnosed or relapsed multiple myeloma. The goal is to se…

This study tests whether light therapy (photobiomodulation) can prevent mouth sores in children receiving chemotherapy. Fifty children aged 0-30 will receive daily light treatments during hospital stays and at home. Researchers will check if the therapy is easy to use and accepta…

This study will test different methods to prevent infections and other problems from central lines (tubes placed in large veins) in 2,500 patients. It compares special antimicrobial caps and a skin anchor device against standard care. The goal is to find the best ways to keep pat…

This study tests whether the supplement glutamine can prevent nerve damage caused by the chemotherapy drug vincristine in children and teens with cancer. About 70 participants, aged 6 to 18, will take glutamine twice daily for 14 days during their treatment. Researchers will trac…

This study tests whether using an immersive virtual reality headset during exercise can improve motivation, adherence, and emotional well-being in adults undergoing cell therapy or stem cell transplant. Participants follow a therapeutic exercise program with or without VR. The tr…

This study tests if eating only within an 8-hour window each day (time-restricted eating) can reduce treatment side effects and improve quality of life for people with solid tumors starting adjuvant therapy after surgery. Fifty adults will be randomly assigned to follow this eati…

This study tests whether an AI-based website that gives personalized diet tips and recipes can help cancer patients who experience taste changes during therapy. About 198 adults with certain cancers (like multiple myeloma, melanoma, or GI cancers) will either get the AI tool or a…

This pilot study tests whether a dietitian-led High Fiber Program can help patients increase their fiber intake after receiving a stem cell transplant from a donor. The goal is to improve gut health and possibly reduce complications like graft-versus-host disease. About 44 adults…

This phase II trial tests whether low-dose psilocybin, a compound from magic mushrooms, combined with psychotherapy is safe and effective for easing chronic pain in cancer patients who already take opioids. Twenty adults with active cancer and moderate to severe pain will receive…

This study tests whether a cannabis gummy can improve sleep and quality of life in 50 cancer patients who have trouble sleeping. Participants will either take the gummy or receive usual care for 5 weeks. The goal is to see if the gummy is safe and helps with sleep, while also che…

This study tests whether a seven-session, telehealth-based therapy called Meaning-Centered Psychotherapy is practical and helpful for stem cell transplant survivors and their main caregivers. The program aims to help dyads stay connected to meaning, cope with difficult experience…

This study tests whether using a virtual reality headset for guided muscle relaxation can help people undergoing cell therapies like CAR-T or stem cell transplant feel better. Participants will use the VR headset once daily for up to 20 minutes during their hospital stay. Researc…

This study tests whether sucking on ice chips during chemotherapy can prevent or reduce the severity of painful mouth sores (oral mucositis) in cancer patients. 102 adults receiving 5-fluorouracil or methotrexate will be randomly assigned to either get ice chips during infusion p…

This study tests whether a mind-body resilience group program can help lymphoma survivors cope better after finishing treatment. Researchers will enroll 254 adults who are within two years of completing curative therapy. Participants will either receive enhanced usual care or joi…

This study tests whether a 6-week dance-based exercise program can reduce nerve pain and improve quality of life in cancer patients who have nerve damage from chemotherapy. About 76 adults with solid tumors will either join the dance program or receive usual care. The goal is to …

This study looks at whether people with multiple myeloma can safely give themselves the drug daratumumab at home instead of going to the hospital. About 50 patients will take turns receiving the injection at home and at the clinic to compare the two approaches. The goal is to see…

This study tests a mobile app designed to encourage physical activity in adolescents aged 12-18 who have completed treatment for blood cancers like leukemia or lymphoma. Thirty participants will either use the app or receive usual care. The main goal is to see if a larger study i…

This study tests whether a robotic dog named AIBO can improve emotional well-being and quality of life in children aged 8-15 with blood cancers who are undergoing a stem cell transplant. The children will interact with AIBO while isolated in the hospital for about 30 days. Resear…

This study tests a painless light treatment called photobiomodulation for children aged 3 to 14 who get severe mouth sores from chemotherapy. The treatment uses a handheld red light device for about 5-10 minutes daily for four days, alongside standard care. Researchers want to se…

This study tests whether a 15-minute hand and foot exercise routine can reduce nerve pain caused by Taxane chemotherapy in cancer patients. Fifty-eight adults with mild nerve symptoms will either do the exercises plus standard care or receive standard care alone. Researchers will…

This pilot study tests whether freeze-dried miracle fruit (MiraBurst) can improve taste changes in people with solid tumors undergoing cancer treatment. About 45 adults will take one mini-square before each meal for 90 days. The goal is to see if this simple supplement can ease a…

This study tests whether doing art activities (like drawing or painting) can reduce fatigue, anxiety, and improve quality of life in adults with blood cancers. Fifty-two patients will be split into two groups: one gets six art sessions over two weeks, the other gets standard care…

This study tests whether adding geriatric-guided care—including nutritional and physical therapy support—improves quality of life for elderly patients with diffuse large B-cell lymphoma. About 170 patients aged 70 and older who are unfit or frail will receive either this extra su…

This study tests whether a resilience-building program can improve quality of life for lymphoma survivors who finished treatment within the last two years. Researchers will compare the program to a standard health education class. The goal is to help survivors feel better physica…

This study tests whether taking a specific probiotic (Lactobacillus rhamnosus GG) with a special form of vitamin B2 for 12 weeks can improve memory and thinking in adults over 65 who have mild memory problems. Researchers will measure changes in cognitive tests and brain activity…

This study tests if taking fish oil by mouth can prevent or lessen nerve damage (peripheral neuropathy) caused by the chemotherapy drug bortezomib in people with multiple myeloma. Researchers will compare nerve health in 200 patients who take fish oil versus those who don't. The …

This study tests whether orthopedic check-ups and custom exercise plans can improve physical function and rehabilitation in people with multiple myeloma who have bone lesions. About 71 newly diagnosed patients will receive ongoing bone stability assessments and tailored exercise …

This study tests whether a traditional Chinese medicine hand-foot soak can reduce nerve pain and skin reactions caused by chemotherapy. About 300 adults with solid tumors who have these side effects will use the soak. The goal is to see if it improves symptoms and quality of life…

This study tests whether adding a controlled breathing program to a standard exercise routine improves heart and lung function in people with multiple myeloma. Twenty-six adults currently on treatment will take part in a 6-week program. One group will do breathing exercises at ho…

This study looks at whether adding a controlled breathing routine to a standard exercise program can reduce physical symptoms like pain and fatigue in adults with multiple myeloma. About 32 participants will take part in a 6-week program, with some doing extra breathing exercises…

This study tests whether a 16-week lifestyle program focused on nutrition and physical activity can improve physical function, quality of life, and biological aging markers in people with multiple myeloma. About 184 participants will be randomly assigned to either start the progr…

This study looks at whether a special education program and a check-in on caregivers' own needs can boost the quality of life for people caring for someone with multiple myeloma. About 27 caregivers will take part. The goal is to see if this extra support helps them feel better a…

This study tests whether virtual palliative care (via video calls) works as well as standard in-person care for adults with cancer. About 252 participants will be randomly assigned to one of the two approaches. Researchers will measure quality of life, symptom burden, and satisfa…

This study looks at whether a 12-week resistance exercise program can improve quality of life, reduce frailty, and boost mental health in people with multiple myeloma. Fifty patients will be split into two groups: one doing supervised exercise and the other doing the same exercis…

This study tests whether a peppermint oil mouthwash can help reduce nausea, vomiting, and loss of appetite caused by chemotherapy in people with blood cancers. 72 patients will be split into two groups: one gets standard oral care, the other rinses with peppermint oil three times…

This study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…

This observational study will review medical records of about 100 adults with multiple myeloma that has returned after initial treatment. Researchers want to see how well belantamab mafodotin given with other drugs (bortezomib and dexamethasone, or pomalidomide and dexamethasone)…

This observational study will follow 30 multiple myeloma patients receiving a standard CAR-T therapy called cilta-cel. Researchers will collect blood, bone marrow, and other samples to find biomarkers linked to rare toxicities like nerve damage, blood issues, and gut problems. Th…

This study looks at how the age of a stem cell donor affects outcomes for people with blood cancers. Researchers will analyze data from 5,000 patients who received a first stem cell transplant, comparing those who got cells from younger versus older donors. The goal is to provide…

This study looks at whether using a cousin as a stem cell donor works as well as using a sibling for people with blood cancers. Researchers will compare survival, relapse, and side effects like graft-versus-host disease in patients who received a transplant from either a cousin o…

This study looks at thinking skills, memory, and quality of life in people who are 3 to 5 years past successful treatment for Hodgkin lymphoma or certain types of B-cell lymphoma. Participants take a series of tests and questionnaires once during a regular follow-up visit. The go…

This observational study will analyze tissue samples from 400 people with MALT lymphoma, a slow-growing cancer. Researchers aim to build a comprehensive molecular and cellular map of the disease across different body sites. The goal is to identify tumor subtypes and biomarkers th…

This study examines tumor samples from 100 people diagnosed with primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL), a rare cancer that starts in the brain or spine. Researchers will use advanced genetic and molecular techniques to identify patterns in the …

This study aims to create a score that uses a special blood test to predict bleeding risk in people with blood cancers and very low platelet counts. Researchers will take an extra blood sample from 410 participants and analyze it with viscoelastometric tests. The goal is to ident…

This pilot study tests a new imaging method called PET-enabled dual-energy CT to measure bone and soft tissue in the bone marrow. It will include 45 adults: some with multiple myeloma scheduled for CAR T-cell therapy and some healthy volunteers. The goal is to see if this new met…

This study will test whether doctors can quickly and accurately monitor minimal residual disease (tiny amounts of cancer left after treatment) in people with aggressive B-cell lymphoma. Researchers will use blood tests to look for tumor DNA and PET scans to see if results can be …

This study tracks how the experimental drug AZD1390 moves through and leaves the body after a single dose. It involves about 8 adults with advanced solid tumors who are not currently on active cancer treatment. By using a tiny radioactive label, researchers can measure the drug i…

This study collects blood and bone marrow samples from 80 people with B-cell non-Hodgkin lymphoma to explore why some cancers resist chemotherapy. Researchers will analyze the tumor and its environment, and develop lab models to test new treatments. The goal is to uncover resista…

This study looks at why some people with blood cancers like multiple myeloma or lymphoma choose not to receive treatment at home, or are not eligible for it. Researchers will interview patients, their caregivers, and healthcare staff, and review medical records and questionnaires…

This observational study will follow 107 children and adults with B-cell acute lymphoblastic leukemia who are treated with approved CAR-T cell therapies in Italy. Researchers will collect data from medical records to see how many patients achieve a response. The goal is to unders…

This early-phase study looks at how the drug combination BVd (belantamab mafodotin, bortezomib, and dexamethasone) is processed by the body in people with multiple myeloma who also have moderate liver problems. About 20 participants will be enrolled to compare drug levels and saf…

This study tests whether a survivorship care plan is practical for blood cancer patients who have had a stem cell transplant. Researchers will track how many patients stick with the program and measure their quality of life, unmet needs, and caregiver burden. The goal is to see i…

This early-stage study looks at whether taking oral paclitaxel with encequidar on an empty stomach or after a meal changes how much drug gets into the body. About 46 adults with advanced solid tumors (like breast, lung, or stomach cancer) will take the drugs in different sequence…

This Italian registry will follow 50 adults with relapsed/refractory multiple myeloma who are receiving elranatamab as part of their standard care. The goal is to track how many infections occur during the first year of treatment. The study does not test a new drug but aims to ga…

This study will follow 225 blood cancer patients receiving CAR-T therapy, bispecific antibodies, or high-dose chemotherapy with stem cell transplant. Researchers will test memory, attention, and thinking skills before treatment and up to 3 years after. The goal is to understand h…

This early-stage study will give a single dose of MDR-001, a GLP-1 receptor agonist tablet, to 32 people: some with mild or moderate liver impairment and some with healthy livers. Researchers want to see how the drug moves through the body and if it is safe in people with liver i…

This study looks at how people with blood cancers (like leukemia, lymphoma, or myeloma) in France use complementary and alternative medicines (CAM), such as acupuncture or herbal remedies. Researchers will survey 85 patients and interview some to understand why they use these the…

This study will review medical records of 300 UK patients with newly diagnosed multiple myeloma who cannot have a stem cell transplant and are treated with a three-drug combination (daratumumab, lenalidomide, and dexamethasone). The goal is to see how well this therapy works in e…

This study surveys primary care doctors and nurse specialists in the West Midlands to understand how they decide to refer patients with chronic lymphocytic leukemia (CLL) to specialists. The goal is to identify differences in referral practices and find ways to make care more equ…

This study will measure two immune system markers, CD305 and CD85d, on cancer cells from 180 people newly diagnosed with B-cell blood cancers. The goal is to see how these markers relate to different cancer types and patient outcomes. No treatment is given; the study only observe…

This study looks at whether the bacteria living in your gut can influence how well a drug called glofitamab works against diffuse large B-cell lymphoma (DLBCL). Researchers will collect stool samples from 30 patients before and after treatment to track changes in gut microbiome a…

This study will check how common parasitic infections are in 285 people with blood disorders, like anemia or blood cancers, at Assiut University hospitals in Egypt. Researchers will test for Toxoplasma and other parasites. The goal is to understand if routine screening could help…

This study will interview 30 children aged 6-17 who are undergoing chemotherapy for cancer, along with their parents, to understand how they deal with changes in taste, smell, and food texture. The goal is to learn what coping strategies families use at home and in the hospital t…

This study checks if a short questionnaire called G8 can correctly identify frailty in people aged 70 and older with solid tumors. Researchers will compare the G8 results with a full geriatric assessment in 150 patients. The goal is to see if the G8 tool works well for Portuguese…

This study will check if old tissue samples from 15 patients with extramedullary multiple myeloma can be used to find new biomarkers. Researchers will look at the samples and medical records to see if they are good enough for future research. No new treatments or tests are given—…

This study will check if stored tissue samples from 20 people with a specific type of multiple myeloma (t(4-14)) can be used to find new biomarkers. No new treatments or tests are given. The goal is to see if the samples are good enough for research.

This study looks for biological markers in tumor tissue and blood that may be linked to anxiety and depression in people with solid tumors. Researchers will combine psychological assessments with lab tests to better understand these emotional struggles. The goal is to improve ear…

This study follows 100 adults with certain types of lymphoma who are receiving CAR-T cell therapy. Researchers will test memory, attention, and other thinking skills before treatment and at 6, 12, and 24 months after. The goal is to learn how CAR-T therapy affects brain function …

This study looks at blood cancer patients who carry drug-resistant bacteria in their gut. Researchers want to find out who is most likely to get a serious infection from these bacteria. They will collect rectal swabs and track patients for 90 days to build a prediction tool. The …

This study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…

This observational study will follow 100 children in Denmark who receive a stem cell transplant for blood cancer or other serious blood disorders. Researchers will test their thinking skills, physical abilities, and daily activity before the transplant and for one year after. The…

This study tests whether giving less therapeutic food and requiring fewer clinic visits can still effectively treat severe acute malnutrition in children aged 6-59 months in Kenya. About 2,274 children will take part across 45 health facilities. The goal is to find a treatment ap…

This study looks at 50 adults with primary central nervous system lymphoma who are receiving high-dose methotrexate, a key chemotherapy. The goal is to see if measuring the drug early in the blood can predict later kidney problems. By identifying at-risk patients sooner, doctors …

This Phase 1 trial tests QL2109, a biosimilar to the multiple myeloma drug Darzalex, in 102 healthy Chinese men. The goal is to see if the body processes QL2109 similarly to Darzalex and to check for side effects. It does not test the drug's ability to treat cancer.

This study follows 65 patients getting stem cell transplants for blood cancers to see how their immune systems rebuild. Researchers will track B cells and antibody responses to vaccines before and after transplant. The goal is to improve vaccination schedules and infection protec…

This study will check if certain blood cell markers, called reticulocytes, can serve as early signs of bone marrow activity in people with chronic B lymphoproliferative neoplasms, a type of blood cancer. Researchers will measure reticulocyte counts and maturity levels in 120 newl…

This study looks at what happens to people with diffuse large B-cell lymphoma (a common blood cancer) after treatment with polatuzumab vedotin stops working. Researchers will track 200 patients in China to see which salvage treatments are used and how well they work. The goal is …

This early study tests a new PET imaging agent called 68Ga-NOTA-BCMA to see if it can safely and accurately show where anti-BCMA CAR-T cells go in the body and how long they last. Ten adults with multiple myeloma who are scheduled for CAR-T therapy will receive the tracer and und…

This observational study follows 162 patients with blood cancers who are receiving either a stem cell transplant or CAR-T therapy. Researchers will use a questionnaire to measure how symptoms and quality of life change from the start of hospital stay to discharge. The goal is to …

This study looks at medical records of 15,000 adults with chronic B-cell cancers to compare the risk of developing atrial fibrillation (an irregular heartbeat) between two drugs, zanubrutinib and acalabrutinib. Researchers will analyze data from a health database to see which dru…

This study looks at how a personalized strength training program affects people with different cancers, including lung, colon, breast, and blood cancers. 150 adults will either do supervised strength training plus home exercises, or just home exercises, for 12 weeks. Researchers …

This study aims to develop a simple blood test that checks how well a person's immune cells can fight blood cancer. Researchers will collect blood samples from 166 adults with blood cancers to measure immune cell activity and look at genetic factors. The goal is to create a test …

This study creates a registry of 500 cancer patients receiving immunotherapy to better understand and manage immune-related side effects (irAEs). Researchers will collect data on who gets these side effects, how they present, and what treatments work best. The goal is to improve …

This study aims to adapt a questionnaire called PROFFIT, originally developed in Italy, to measure financial toxicity (the financial burden of cancer treatment) in Turkish patients. Researchers will enroll 320 adults with cancer who have received treatment in the last three month…

This observational study looks at how immune checkpoint inhibitors (a type of cancer immunotherapy) affect ovarian function and fertility in women aged 18-38 with solid tumors. Researchers will collect blood and stool samples before and during treatment to measure hormone levels …

This study will observe 300 people with advanced lung or gastrointestinal cancers who receive adebrelimab combined with other treatments. Researchers will track side effects and how well the cancer responds. It is a real-world study, meaning it watches what happens in regular med…